The Complete Inherited Disease Panel Test, available at DNA Labs UAE for a cost of 7200 AED, is a comprehensive genetic screening tool designed to identify the presence of genetic mutations associated with a wide range of inherited diseases. This cutting-edge test covers a vast array of genetic disorders, offering individuals and families crucial insights into their genetic health and predisposition towards various inherited conditions. By analyzing the DNA, this panel can detect mutations that could lead to conditions such as cystic fibrosis, sickle cell anemia, various forms of heart disease, and many others, enabling early detection and intervention strategies. Conducted in the state-of-the-art facilities of DNA Labs UAE, the test ensures accuracy, confidentiality, and professional guidance throughout the testing process.
The Comprehensive Hereditary Cancer Panel 154 Genes Test, available at DNA Labs UAE for 7200 AED, is a state-of-the-art genetic screening designed to assess an individual's risk for various hereditary cancers. This extensive test analyzes 154 genes known to be associated with an increased risk of developing cancer, including but not limited to breast, ovarian, colorectal, and pancreatic cancers. By examining a person's DNA, the test identifies specific mutations that could signify a higher likelihood of cancer, enabling early detection and proactive management strategies. The results from this panel can provide valuable information for both the individual tested and their family members, as certain genetic mutations may be inherited. Conducted in the advanced facilities of DNA Labs UAE, this test is a powerful tool in the ongoing fight against cancer, offering individuals insights into their genetic makeup and helping them make informed decisions about their health and preventive care.
The "Congenital Myopathy Gene Panel Test" is a sophisticated diagnostic tool offered by DNA Labs UAE, designed to identify genetic mutations associated with congenital myopathies. These are a group of muscle disorders that are present from birth, causing muscle weakness and hypotonia (reduced muscle tone) among other symptoms. The test specifically targets genes known to be linked to various forms of congenital myopathies, enabling healthcare providers to make accurate diagnoses, understand the severity of the condition, and tailor treatment plans accordingly.
At a cost of 7200 AED, this comprehensive test is an investment in precision medicine, allowing for early intervention strategies and improved patient outcomes. By analyzing a patient's DNA, the test can pinpoint specific genetic anomalies responsible for the myopathy, guiding decisions on management and care. Conducted in the state-of-the-art facilities of DNA Labs UAE, the Congenital Myopathy Gene Panel Test represents a significant step forward in the personalized treatment of congenital muscle disorders, offering hope and clarity to affected individuals and their families.
The "Deafness Gene Panel Test," available at DNA Labs UAE, is a comprehensive genetic screening designed to identify mutations in genes known to be associated with hearing loss. Priced at 7200 AED, this test is a valuable tool for individuals who are experiencing hearing difficulties or have a family history of deafness. By analyzing a wide array of genes linked to various forms of hereditary deafness, the test can provide insights into the genetic basis of an individual's hearing loss, facilitating personalized treatment and management strategies. Conducted in a state-of-the-art facility, the Deafness Gene Panel Test at DNA Labs UAE represents a critical step forward in the diagnosis and understanding of genetic hearing loss conditions.
The Dystonia Gene Panel Test, available at DNA Labs UAE, is a sophisticated diagnostic tool designed to identify genetic mutations associated with dystonia, a complex neurological movement disorder. This condition is characterized by involuntary muscle contractions, leading to repetitive movements or abnormal postures. Dystonia can affect just one muscle, a group of muscles, or muscles throughout the body, and it can be a primary condition or a symptom of another disease.
The test, which costs 7200 AED, involves analyzing a comprehensive panel of genes known to be linked to various forms of dystonia. By examining a patient's DNA, the test aims to pinpoint specific genetic abnormalities that may be causing or contributing to the disorder. This targeted approach not only aids in confirming a diagnosis of dystonia but also helps in understanding the type and potential severity of the condition. Furthermore, the results can guide treatment decisions, assist in predicting the course of the disease, and provide valuable information for family planning.
DNA Labs UAE employs state-of-the-art genetic testing technology to ensure accurate and reliable results. The test is performed under strict quality controls and is interpreted by experts in genetics and neurology. For individuals exhibiting symptoms of dystonia or those with a family history of the disorder, the Dystonia Gene Panel Test offers a crucial step towards achieving a clearer understanding of their condition and exploring appropriate treatment options.
Early Infantile Epileptic Encephalopathy (EIEE), also known as Ohtahara Syndrome, is a severe neurological condition characterized by frequent seizures and significant developmental delays. These seizures typically begin in the first few months of life and are often resistant to treatment. Due to its genetic underpinnings, understanding the specific genetic mutations involved can be crucial for diagnosis, management, and treatment planning.
The Early Infantile Epileptic Encephalopathy Gene Panel Test is a comprehensive diagnostic tool designed to identify genetic mutations associated with EIEE. By analyzing a broad array of genes known to be linked to this condition, the test provides valuable insights that can guide medical professionals in tailoring the most effective treatment strategies for each individual patient.
Administered at DNA Labs UAE, a leading facility in genetic testing, the test ensures high accuracy and reliability. The test cost is set at 7200 AED, reflecting the extensive analysis and expert interpretation involved in identifying the genetic factors contributing to the condition. Through this test, families and healthcare providers can gain a deeper understanding of the disorder, paving the way for personalized treatment approaches and improved outcomes for affected infants.
The Clinical Exome Trio Sequencing Test is a comprehensive genetic screening process designed to identify the genetic causes of inherited diseases within a family. Conducted at DNA Labs UAE, this advanced diagnostic test involves sequencing the exomes—the parts of the genome that encode proteins—of three individuals, typically the child and both parents. This trio approach significantly enhances the ability to pinpoint disease-causing mutations by comparing the child's genetic information with that of the parents, thereby offering insights into the inheritance patterns and potential genetic disorders.
The test is particularly useful in cases where a child presents with symptoms of a genetic disorder that has not been diagnosed through other means. It can identify mutations in over 20,000 genes, covering a vast array of inherited conditions, including rare diseases that may not be detected through standard genetic tests. The Clinical Exome Trio Sequencing Test is invaluable for families seeking answers to complex genetic health puzzles, offering a pathway to targeted treatment options and personalized medical care.
The cost of the Clinical Exome Trio Sequencing Test at DNA Labs UAE is 12,000 AED. This investment covers the comprehensive analysis and detailed reporting necessary to understand the genetic underpinnings of inherited conditions, making it a critical step for families in pursuit of diagnosis, informed decision-making, and management of genetic disorders.
The Oncomine Breast cfTNA Assay Test is a cutting-edge diagnostic tool designed for the detection and analysis of circulating free tumor nucleic acids (cfTNA) in the plasma of patients with breast cancer. This highly sensitive and specific assay is utilized to identify and quantify genetic mutations and alterations in breast cancer DNA, providing critical insights that can guide personalized treatment strategies.
Performed at DNA Labs UAE, a leading facility in genetic testing and analysis, the Oncomine Breast cfTNA Assay Test harnesses next-generation sequencing technology to offer a comprehensive genomic profile of a patient's breast cancer. This non-invasive approach allows for the monitoring of disease progression and response to treatment without the need for traditional, more invasive biopsy methods.
The cost of the Oncomine Breast cfTNA Assay Test at DNA Labs UAE is 9600 AED. While the price may seem high, the value it provides in terms of precise cancer characterization and the potential to tailor treatment plans to individual genetic profiles makes it a valuable tool in the fight against breast cancer. This test represents a significant advancement in oncology, offering hope for improved outcomes through personalized medicine.
The Oncomine Focus Panel and PD-L1 Test, offered by DNA Labs UAE for a cost of 10,500 AED, represents a cutting-edge approach in the field of precision medicine, specifically designed to cater to patients with various types of cancer. This comprehensive test combines the strengths of the Oncomine Focus Panel, which utilizes next-generation sequencing technology to identify key genetic alterations across a wide array of cancer-related genes, with the PD-L1 test that measures the expression of the PD-L1 protein in cancer cells.
The Oncomine Focus Panel targets a curated list of genes associated with cancer, enabling clinicians to pinpoint specific mutations and alterations that could influence treatment decisions. By identifying these genetic markers, healthcare providers can recommend more personalized and effective therapy options for patients, such as targeted therapies or immunotherapies that are best suited to their genetic profile.
The PD-L1 test adds another layer of precision by assessing the level of PD-L1 expression, a protein that plays a crucial role in suppressing the immune response against cancer cells. High levels of PD-L1 on tumor cells may indicate that certain immunotherapies, which block the PD-L1 pathway and thus boost the immune system's ability to fight cancer, could be particularly beneficial for the patient.
Conducted at the state-of-the-art facilities of DNA Labs UAE, this combined testing approach offers a robust tool in the personalized treatment of cancer, aiming to improve outcomes by tailoring therapies to the unique genetic makeup of each patient's tumor.
The Oncomine Lung cfTNA Cancer Panel Test, available at DNA Labs UAE for a cost of 10,500 AED, is a highly advanced diagnostic tool designed for the detection and analysis of circulating free tumor nucleic acids (cfTNA) in the blood of patients suspected to have lung cancer. This non-invasive test utilizes next-generation sequencing (NGS) technology to identify genetic mutations and alterations in cfTNA that are associated with lung cancer. By analyzing a simple blood sample, the test can provide critical information on the genetic makeup of lung tumors, aiding clinicians in making more informed decisions regarding treatment strategies. This approach not only offers a convenient alternative to traditional tissue biopsies but also enables the monitoring of tumor dynamics and resistance mechanisms over time. DNA Labs UAE, by offering this cutting-edge test, demonstrates its commitment to providing state-of-the-art diagnostic solutions to improve patient care and outcomes in the fight against lung cancer.
